AXSM: Axsome Corp Forward P/S Multiple
Axsome Therapeutics (AXSM) is implementing advanced chemical methods to combat migraine and depression. The forward P/S trend visualizes market expectations, where 8.80 reflects the metric's baseline. Debt optimization is based on robust scientific potential in Alzheimer's therapy and rapid sales scaling, which effectively increases the net margin through operating leverage.
Metric breakdowns and analytics for Axsome Corp (AXSM)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Axsome Therapeutics|AXSM - Long-Term Debt to Capital|Short-Term Debt to Equity Axsome Therapeutics|AXSM - Company Aggregate Indebtedness|Debts to Book Capitalization Axsome Corp|AXSM - Long-Term Debt|Company Current Liabilities Axsome Therapeutics|Quick Liquidity Indicator axsome.com
- financial results and valuation multiples details:
AXSM - Profit After Payment of Taxes|Projected Future Earnings Axsome Therapeutics|AXSM - Business Payback Period|Forward P/E Multiple Axsome Therapeutics Inc|AXSM - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axsome Corp|AXSM - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Axsome Therapeutics|AXSM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months axsome.com|AXSM - Earnings per share growth this year|Net earnings per share growth forecast for next year Axsome Therapeutics
- revenue and sales details:
Fundamental valuation:Axsome Therapeutics, Inc. AXSM
The active expansion of Axsome Therapeutics (AXSM) drug distribution across neurological clinics directly impacts the trajectory of the company's forward P/S chart. This indicator compares current market capitalization with projected annual revenue, allowing investors to assess the level of market optimism priced in and determine the risk of the asset being overbought relative to expected sales growth rates.
Competitor analysis
Biogen - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NBIX (Neurocrine)|Regencell - Forward P/S Multiple|Forward Price to Sales ACAD (ACADIA Corp)|XENE: Forward P/S Multiple|Market Cap to Future Revenue Ratio vikingtherapeutics.com (VKTX)|Price-to-Projected Revenue Ratio Supernus|CPRX: Forward Price to Sales|Forward P/S Multiple DNLI|Forward P/S Multiple Harmony Corp (HRMY)|Price-to-Projected Revenue Ratio Biohaven Ltd. BHVN|AMLX (amylyx.com) - Future Price to Revenue|Trevi Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Praxis Precision Medicines Inc|AVXL (Anavex Corp) - Forward Price-to-Revenue Multiple|CeriBell EEG (CBLL) - Forward P/S Multiple|Forward Price-to-Revenue Multiple PRTA|ALEC (Alector Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple ANNX|Market Cap to Expected Sales Ratio omeros.com|Forward P/S Multiple NGNE (Neurogene Corp)|ACIU - Forward Price-to-Revenue Multiple|VYGR - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio neumoratx.com NMRA|SCLX: Forward P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ACOG|Market Cap to Projected Revenue CGTX (Cognition Therapeutics Inc.)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|Market Cap to Expected Sales Ratio cassavasciences.com|Price-to-Projected Revenue Ratio Assertio ASRT|COYA - Forward Price-to-Revenue Multiple|VTGN - Price-to-Projected Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Projected Revenue|ABOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|Forward Price-to-Revenue Multiple ATHE|Forward P/S Multiple Clene Nanomedicine|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|Grace Tx - Forward P/S Multiple|AIFF - Forward P/S Multiple|KLTO (anewmeds.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue NRSN|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|MetaVia, Inc. (MTVA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP - Forward Price-to-Revenue Multiple|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio athira.com|ADXN (Addex Therapeutics Ltd) - Forward Price-to-Revenue Multiple|Alzamend Neuro - Forward Price to Sales|Forward Price-to-Revenue Multiple CYCN|PTIX (Protagenic) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|CRGT (cortigent.com) - Forward Price to Sales|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. (BCLI) - Market Cap to Future Revenue Ratio|CARA - Price-to-Projected Revenue Ratio|Forward Price to Sales CHRO (Chromocell)|ELYM: Forward P/S Multiple|Intra-Cellular Therapies, Inc. (ITCI) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Marinus Pharmaceuticals Inc - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO - Market Cap to Future Revenue Ratio|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple synaptogen.com SNPX|TRVN: Forward Price-to-Revenue Multiple|Vigil Neuroscience - Price to Expected Revenue Ratio|WENA: Forward P/S Multiple|CERE - Market Cap to Expected Sales Ratio
